- Trials with a EudraCT protocol (98)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
98 result(s) found for: Protein design.
Displaying page 1 of 5.
EudraCT Number: 2006-000562-36 | Sponsor Protocol Number: BIG2-06/N063D/EGF106708 | Start Date*: 2007-05-04 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: ALTTO (Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) study. A randomised, multi-centre, open-label, phase III study of adjuvant lapatinib, trastuzumab, their sequence and their comb... | |||||||||||||
Medical condition: Operable primary breast cancer with over expression/ amplification of HER2. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IE (Completed) HU (Completed) FR (Completed) GB (Completed) SK (Completed) EE (Completed) CZ (Completed) DK (Completed) BE (Completed) DE (Completed) GR (Completed) NL (Completed) IT (Completed) ES (Completed) SI (Completed) BG (Completed) AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-003511-31 | Sponsor Protocol Number: V99P2 | Start Date*: 2008-07-16 |
Sponsor Name:Novartis Vaccines and Diagnostics GmbH & Co. KG | ||
Full Title: Phase I/II, Randomized, Observer-blind, Placebo-controlled, Single-Center Study of the Tolerability, Immunogenicity and Efficacy (following Helicobacter pylori infectious challenge) of Novartis’ In... | ||
Medical condition: no medical condition: healthy subjects | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2007-002962-37 | Sponsor Protocol Number: NA_00008675 | Start Date*: 2010-09-14 |
Sponsor Name:VU Medical Center Amsterdam | ||
Full Title: Phase I/II study of dalteparin, a low molecular weight heparin (LMWH), in combination with Sunitinib (SU11248), an oral, selective multitargeted tyrosine kinase inhibitor, as first line treatment, ... | ||
Medical condition: Patients with metastatic or inoperable renal cell cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2021-000545-40 | Sponsor Protocol Number: FELZ01 | Start Date*: 2021-08-01 |
Sponsor Name:Medical University of Vienna | ||
Full Title: Safety, Tolerability and Efficacy of Monoclonal CD38 Antibody Felzartamab in Late Antibody-Mediated Renal Allograft Rejection – A Phase 2 Pilot Trial | ||
Medical condition: Late active or chronic active antibody-mediated rejection | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Trial now transitioned) DE (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2011-000631-92 | Sponsor Protocol Number: CQGE031A2208 | Start Date*: 2011-12-07 | |||||||||||
Sponsor Name:Novartis Pharma AG | |||||||||||||
Full Title: A phase II, randomized, double-blind, placebo controlled, parallel design, dose ranging, multi-center trial of four levels of exposure of QGE031 s.c. for 16 weeks in subjects aged 18 years and olde... | |||||||||||||
Medical condition: Peanut allergy | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Prematurely Ended) GB (Prematurely Ended) GR (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-003371-34 | Sponsor Protocol Number: CDI-CS-002 | Start Date*: 2015-02-20 | ||||||||||||||||
Sponsor Name:Basilea Pharmaceutica International Ltd. | ||||||||||||||||||
Full Title: An open-label Phase 1/2a study of oral BAL101553 in adult patients with advanced solid tumors and in adult patients with recurrent or progressive glioblastoma or high-grade glioma | ||||||||||||||||||
Medical condition: Advanced or recurrent solid tumors, recurrent or progressive glioblastoma, or high-grade glioma | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) BE (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2012-001877-94 | Sponsor Protocol Number: COX-2I | Start Date*: 2012-09-17 |
Sponsor Name:UNIVERSITY CLINIC GOLNIK | ||
Full Title: Significance of COX-2 inhibition in first line treatment of extensive disease small-cell lung cancer (ED-SCLC) | ||
Medical condition: extensive disease small-cell lung cancer (ED-SCLC) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SI (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2005-000311-98 | Sponsor Protocol Number: P2005V3 | Start Date*: 2005-11-09 |
Sponsor Name:University of Nottingham | ||
Full Title: A randomised controlled trial (pilot study) of the use of macerated garlic oil in patients with cystic fibrosis who have pulmonary infection with Pseudomonas aeruginosa | ||
Medical condition: Chronic pulmonary infection with Pseudomonas aeruginosa in patients with cystic fibrosis | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2018-003451-38 | Sponsor Protocol Number: OVG2018/05 | Start Date*: 2019-02-21 |
Sponsor Name:Clinical Trials and Research Governance (CTRG) | ||
Full Title: Immunogenicity and reactogenicity of concomitantly administered hexavalent and Group B meningococcal vaccines in infancy. | ||
Medical condition: Immunogenicity and reactogenicity of concomitantly administered hexavalent and group B meningococcal vaccines in infancy. | ||
Disease: | ||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) | ||
Trial results: View results |
EudraCT Number: 2020-004070-22 | Sponsor Protocol Number: CV-NCOV-003 | Start Date*: 2021-04-12 | |||||||||||
Sponsor Name:CureVac AG | |||||||||||||
Full Title: COVID-19: A Phase 3 multicenter clinical trial to evaluate the safety, reactogenicity and immunogenicity of the investigational SARS-CoV-2 mRNA vaccine CVnCoV in adults 18 years of age and above wi... | |||||||||||||
Medical condition: Vaccination for prophylaxis of COVID-19 (adults with co morbidities) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-001937-40 | Sponsor Protocol Number: EORTC 16032-18031 | Start Date*: 2005-05-19 | |||||||||||
Sponsor Name:European Organisation for Research and Treatment of Cancer | |||||||||||||
Full Title: Randomized, open phase II study of immunization with the recombinant MAGE-3 protein combined with adjuvant AS02B or AS15 in patients with unresectable and progressive metastatic cutaneous melanoma | |||||||||||||
Medical condition: Unresectable and progressive metastatic cutaneous melanoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-001429-33 | Sponsor Protocol Number: IM140-103 | Start Date*: 2014-11-24 | |||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||
Full Title: Open Label, Adaptive Design, Ascending, Multiple-Dose Study to Evaluate Safety and Efficacy of BMS-986004 in Adult Subjects with Primary Immune Thrombocytopenia (ITP) | |||||||||||||
Medical condition: Immune Thrombocytopenia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-003300-11 | Sponsor Protocol Number: 105553 | Start Date*: 2005-11-25 |
Sponsor Name:GlaxoSmithKline Biologicals | ||
Full Title: A phase III randomised, controlled study to assess in a double blind manner the lot-to-lot consistency of three consecutive production lots of GlaxoSmithKline (GSK) Biologicals’ 10-valent pneumococ... | ||
Medical condition: Three dose primary vaccination of healthy infants between 6 and 12 weeks of age at the time of the first vaccination against Streptococcus pneumaniae | ||
Disease: | ||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |
Trial protocol: FI (Completed) | ||
Trial results: View results |
EudraCT Number: 2020-001937-11 | Sponsor Protocol Number: 132333 | Start Date*: 2020-04-30 |
Sponsor Name:University College London | ||
Full Title: A single-site, randomised, controlled, parallel design, open-label investigation of an approved nebulised recombinant human DNase enzyme (dornase alfa) to reduce hyperinflammation in hospitalised p... | ||
Medical condition: Respiratory illness caused by Covid-19 | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) | ||
Trial results: View results |
EudraCT Number: 2021-001624-17 | Sponsor Protocol Number: 210321 | Start Date*: 2021-07-21 |
Sponsor Name:Karolinska University Hospital | ||
Full Title: Safety of oral micronized progesterone versus norethisterone acetate in continuous combination with oral estrogen as menopausal hormone therapy – a double-blind randomized study- PROBES study (Prog... | ||
Medical condition: Climacteric symptoms | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: SE (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2022-000837-17 | Sponsor Protocol Number: NL80854.018.22 | Start Date*: 2022-12-07 |
Sponsor Name:Amsterdam UMC | ||
Full Title: Subcutaneous vedolizumab drug de-escalation using therapeutic drug monitoring in inflammatory bowel disease: a randomized controlled pilot study | ||
Medical condition: Inflammatory bowel diseases (Crohn's disease, ulcerative colitis) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2018-004423-36 | Sponsor Protocol Number: PTG-300-03 | Start Date*: 2019-04-08 | |||||||||||
Sponsor Name:Protagonist Therapeutics, Inc. | |||||||||||||
Full Title: An Open Label Extension Study of PTG-300 in Non-Transfusion Dependent (NTD) and Transfusion-Dependent (TD) β-thalassemia Subjects | |||||||||||||
Medical condition: β-Thalassemia Subjects with Chronic Anemia (transfusion and non transfusion dependent) | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GR (Completed) GB (Completed) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-000824-32 | Sponsor Protocol Number: IMDZ-04-1702 | Start Date*: 2018-10-19 |
Sponsor Name:Immune Design Corp. | ||
Full Title: A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Determine the Efficacy and Safety of CMB305 in Unresectable Locally-advanced or Metastatic NY-ESO-1+ Synovial Sarcoma Subjects Follo... | ||
Medical condition: Unresectable locally-advanced or metastatic synovial sarcoma | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: GB (Prematurely Ended) DK (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2013-005327-16 | Sponsor Protocol Number: | Start Date*: 2014-07-15 | |||||||||||
Sponsor Name:The University of Edinburgh [...] | |||||||||||||
Full Title: A Randomized Open Label Pilot Study to Compare Targinact vs. Oxycodone in Early Return of Gastrointestinal Function after Colorectal Surgery | |||||||||||||
Medical condition: Post-operative pain | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-002455-97 | Sponsor Protocol Number: 13381 | Start Date*: 2016-10-19 | ||||||||||||||||
Sponsor Name:University of Southampton | ||||||||||||||||||
Full Title: Antibiotics for lower Respiratory Tract Infection in Children presenting in Primary Care | ||||||||||||||||||
Medical condition: Respiratory tract infections in children aged between 6 months and 12 years | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Completed) | ||||||||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
